Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Common Equity: 2020-2025

Historic Common Equity for Foghorn Therapeutics (FHTX) over the last 6 years, with Sep 2025 value amounting to -$89.7 million.

  • Foghorn Therapeutics' Common Equity fell 216.96% to -$89.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$89.7 million, marking a year-over-year decrease of 216.96%. This contributed to the annual value of -$45.5 million for FY2024, which is 41.02% up from last year.
  • As of Q3 2025, Foghorn Therapeutics' Common Equity stood at -$89.7 million, which was down 16.96% from -$76.7 million recorded in Q2 2025.
  • Over the past 5 years, Foghorn Therapeutics' Common Equity peaked at $125.2 million during Q1 2021, and registered a low of -$97.5 million during Q1 2024.
  • For the 3-year period, Foghorn Therapeutics' Common Equity averaged around -$56.6 million, with its median value being -$57.4 million (2023).
  • Per our database at Business Quant, Foghorn Therapeutics' Common Equity spiked by 223.67% in 2021 and then crashed by 69,019.64% in 2023.
  • Foghorn Therapeutics' Common Equity (Quarterly) stood at $96.9 million in 2021, then slumped by 99.88% to $112,000 in 2022, then plummeted by 69,019.64% to -$77.2 million in 2023, then soared by 41.02% to -$45.5 million in 2024, then tumbled by 216.96% to -$89.7 million in 2025.
  • Its Common Equity stands at -$89.7 million for Q3 2025, versus -$76.7 million for Q2 2025 and -$61.7 million for Q1 2025.